Targeting Axonal Transport in Alzheimer's Disease Webinar

What Makes a Good Potential Target for Drug Discovery?

Listen in as Dr Elizabeth Glennon, of King's College London, discusses how the disruption of axonal transports early on within Alzheimer's Disease provides excellent targets for drug discovery.

Meet Our Presenter

Elizabeth (Lizzie) Glennon studied her degree in biochemistry at the University of York (UK), followed by a PhD at the Univeristy of Leeds (UK), where she studied molecular mechanisms of neurodegeneration in Alzheimer's disease. Lizzie subsequently moved to King's College London, where she worked as a post doc investigating how a break down in axonal transport may contribute to development of Alzheimers disease.

Lizzie is now an Alzheimer's Research UK fellow at the Institute of Psychiatry, Psychology and Neuroscience at King's College London, where she is investigating how genes linked to Alzheimer's disease could affect the subcellular trafficking of the AD hallmark protein tau.

Webinar Topics

  • How disruption of axonal transport contributes to the development of Alzheimer's disease
  • Mechanisms of axonal transport of the Alzheimer's amyloid precursor protein, and how these are altered in the disease

Other Webinars from Abcam

Life Science Webinars by Subject Matter

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.